Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Badriah M. Almutairi"'
Autor:
Yaseen M. Arabi, Ayed Y. Asiri, Abdullah M. Assiri, Mashan L. Abdullah, Haya A. Aljami, Hanan H. Balkhy, Majed Al Jeraisy, Yasser Mandourah, Sameera AlJohani, Shmeylan Al Harbi, Hani A. Aziz Jokhdar, Ahmad M. Deeb, Ziad A. Memish, Jesna Jose, Sameeh Ghazal, Sarah Al Faraj, Ghaleb A. Al Mekhlafi, Nisreen Murad Sherbeeni, Fatehi Elnour Elzein, Frederick G. Hayden, Robert A. Fowler, Badriah M. AlMutairi, Abdulaziz Al-Dawood, Naif Khalaf Alharbi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Animal and human data indicate variable effects of interferons in treating coronavirus infections according to inflammatory status and timing of therapy. In this sub-study of the MIRACLE trial (MERS-CoV Infection Treated with a Combination o
Externí odkaz:
https://doaj.org/article/e5a94615be554d5c80e9bfc21370cdd0
Autor:
Adel F. Almutairi, Badriah M. Almutairi, Abdullah S. Alturki, Abdallah A. Adlan, Mahmoud Salam, Majed I Al-Jeraisy, Hanan H. Balkhy
Publikováno v:
Journal of Infection and Public Health, Vol 12, Iss 5, Pp 673-680 (2019)
Background: Participation in first-in-human (FIH) clinical trials is a valuable contribution to science. This study aims to investigate the Saudi public’s attitude toward FIH clinical trials, identify their willingness to take part in it, and their
Externí odkaz:
https://doaj.org/article/365fa42dec4d4aefa898679555a990e3
Autor:
null Faizah Alotaibi, null Naif Khalaf Alharbi, null Lindsey B. Rosen, null Ayed Y. Asiri, null Abdullah M. Assiri, null Hanan H. Balkhy, null Majed Al Jeraisy, null Yasser Mandourah, null Sameera AlJohani, null Shmeylan Al Harbi, null Hani A. Aziz Jokhdar, null Ahmad M. Deeb, null Ziad A. Memish, null Jesna Jose, null Sameeh Ghazal, null Sarah Al Faraj, null Ghaleb A. Al Mekhlafi, null Nisreen Murad Sherbeeni, null Fatehi Elnour Elzein, null Badriah M. AlMutairi, null Abdulaziz Al‐Dawood, null Mashan L. Abdullah, null Tlili Barhoumi, null Mohammed W. Alenazi, null Abdulrahman Almasood, null Steven M. Holland, null Yaseen M. Arabi, null the Saudi Critical Care Trials Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee16a1656f989e6e9eef742a95868103
https://doi.org/10.1111/irv.13116/v2/response1
https://doi.org/10.1111/irv.13116/v2/response1
Autor:
Abdullatif Alarfaj, Manar Almaghaslah, Athari Alotaibi, Mohammad Bosaeed, Majed Al-Jeraisy, Yaseen M. Arabi, Hassan Almarhabi, Abderrezak Bouchama, Abdulmajid Al Arfaj, Mohammed Alzahrani, Abdulrahman Alsaedy, Majid Alshamrani, Omar Aldibasi, Malak Alharbi, Hajar Alqahtani, Badriah M. Almutairi, Khalid Ghalilah, Abdullah Bawazir, Nasser Alqahtani, Abdulhakeem O. Althaqafi, Nawaf M. Alyahya, Hawra Albayat, Sameera M. Al Johani, Ahmad Alaskar, Ebrahim Mahmoud, Jumana AlJishi, Faisal M. Alharbi, Hadeel Altayib, Saud AlEisa, Ahmad Alharbi
Publikováno v:
Infectious Diseases and Therapy
Introduction Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc6d88b198d3a07df0676267abc18f8b
https://doi.org/10.1007/s40121-021-00496-6
https://doi.org/10.1007/s40121-021-00496-6
Autor:
Mohammed Bosaeed, Ebrahim Mahmoud, Ahmad Alharbi, Hadeel Altayeib, Hawra Albayat, Faisal Alharbi, Khalid Ghalilah, Abdulmajid Al Arfaj, Jumana AlJishi, Abdullatif Alarfaj, Hajar Alqahtani, Badriah M. Almutairi, Manar Almaghaslah, Nawaf M. Alyahya, Abdullah Bawazir, Saud AlEisa, Abdulrahman Alsaedy, Abderrezak Bouchama, Malak Alharbi, Majid AlShamrani, Sameera Al Johani, Majed Aljeraisy, Mohammed Alzahrani, Abdulhakeem O. Althaqafi, Hassan Almarhabi, Athari Alotaibi, Nasser Alqahtani, Yaseen Arabi, Omar Aldibasi, Ahmad Alaskar
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beee856b4cf4d6c0f3a4286f1a6aca75
https://doi.org/10.2139/ssrn.3829663
https://doi.org/10.2139/ssrn.3829663
Autor:
Omar Aldibasi, Sameera Aljohani, Majed Al-Jeraisy, Ahmad Alharbi, Mohammad Hussein, Ahmad Alaskar, Adel Alothman, Ebrahim Mahmoud, Marwan Nashabat, Badriah M. Almutairi, Abdulrahman Alsaedy, Yaseen M. Arabi, Mohammad Bosaeed, Manar Almaghaslah, Hajar Alqahtani, Abderrezak Bouchama
Publikováno v:
Trials
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Trials, Vol 21, Iss 1, Pp 1-3 (2020)
Objectives The selected combination was based on limited evidence clinically and in vitro on the efficacy of the Favipiravir and Hydroxychloroquine in SARS-CoV-2. The two medications were listed in many guidelines as treatment options and ongoing tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a5b6e89537de8c631c08482e4c2f555
https://doi.org/10.1186/s13063-020-04825-x
https://doi.org/10.1186/s13063-020-04825-x